An analysis of the DELIVER trial also revealed an association between dapagliflozin treatment and reduced risk of cardiovascular death among individuals with heart failure with improved ejection fraction (HFimpEF).
Muscle disease company Dyne Therapeutics, Inc. (DYN) announced Wednesday positive initial clinical data from its ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) and its DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.
an immune response that enables the body to fight cancer on its own. this is what tumour cells in rodents look like before histotripsy. but look at them after. the changing colour shows the immune system has been stimulated to destroy tumour cells. the hope for liver trial is investigating how and why histotripsy triggers this response and how reliably it can be seen in humans. two out of eight patients in a small initial study had this effect. that is, yeah, what i m really hoping for is that you get the immune response and it starts to clear up all of the disease in the liver. cancer experts say histotripsy could be a significant breakthrough. it would be potentially game changing for a lot of cancer patients. you don t need an invasive treatment, you don t need the toxic drugs that we may use in a standard chemotherapy, so you could have an example where you use histotripsy to stimulate the immune system and then you come in with the immune activating drugs, and they might be able
cancer on its own. this is what tumour cells in rodents look like before histotripsy. but look at them after. the changing colour shows the immune system has been stimulated to destroy tumour cells. the hope for liver trial is investigating how and why histotripsy triggers this response and how reliably it can be seen in humans. two out of eight patients in a small initial study had this effect. that is, yeah, what i m really hoping for is that you get the immune response and it starts to clear up all of the things in the liver. cancer experts say histotripsy could be a significant breakthrough. it would be potentially game changing for a lot of cancer patients. you don t need an invasive treatment, you don t need the toxic drugs that we may use in a standard chemotherapy, so you could have an example where you use histotripsy to stimulate the immune system and then you come in with the immune activating drugs and they might be able to then finish off the tumour. but there are some con
so far, including peter. we are about to start a treatment here. professor tze min wah is overseeing his treatment. in the middle, next to the cross, you can see the bubbles. that s the focal point of the treatment. you can hear the sound. so, can you see bits of the tumour being destroyed right now? you can see the focal point is destroying a tumour and, as you can see, the bright area here. early studies have shown histotripsy can also kick start an immune response that enables the body to fight cancer on its own. this is what tumour cells in rodents look like before histotripsy. but look at them after. the changing colour shows the immune system has been stimulated to destroy tumour cells. the hope for liver trial is investigating how and why histotripsy triggers this response and how reliably it can be seen in humans. two out of eight patients in a small initial study had this effect.